Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revottack + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
Revottack + toripalimab is an investigational combination therapy being evaluated for the treatment of advanced malignant solid tumors. **Revottack** is an oncolytic virus based on the vesicular stomatitis virus (VSV) platform, designed to selectively infect, replicate within, and lyse tumor cells while stimulating a systemic anti-tumor immune response. **Toripalimab** is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, blocking its interaction with ligands PD-L1 and PD-L2 to restore T-cell mediated anti-tumor activity. The combination aims to leverage the immunogenic cell death caused by the oncolytic virus to enhance the efficacy of the checkpoint inhibitor, potentially turning "cold" tumors "hot" and improving clinical outcomes in patients with refractory solid malignancies.
- Brand names
- Tuoyi
- Other names
- Vesicular Stomatitis Oncolytic Virus InjectionJS001JS-001JS 001
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Revottack + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revottack + toripalimab.